Skip to content

Author

Gai Liang

We have 2 of 18 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Safety of concurrent immune checkpoint inhibitor therapy during postoperative radiotherapy for triple-negative breast cancer: A preliminary retrospective analysis.

Immune checkpoint inhibitors (ICIs) have recently been approved as part of a neoadjuvant therapy plan for triple-negative breast cancer (TNBC). Consequently, the concurrent use of radiotherapy (RT) and ICIs is becoming increasingly common in clinical practice. Combining RT with ICIs may increase the risk of radiation p...

Gai Liang, Qu Zhang, Meng-Ting Yuan et al. · 0 citations
Review Open access Aug 2026

XBP1 signaling from tumor metabolic stress to myeloid driven immunotherapy resistance (Review)

Targeting XBP1 may enhance the efficacy of existing therapies, particularly immune checkpoint blockade, by alleviating MDSC-mediated immunosuppression, offering a novel paradigm for understanding and reversing tumor immune escape.

Ziwei Chen, Jiaqi Wu, Wen-Xi Liu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.